Hyaluronic acid is a major component of many extracellular matrices that plays a role in the regulation of vasomotor tone and mucous gland secretion, and in the modulation of the inflammatory process in upper and lower airways. This pilot study was aimed at evaluating the effects of nasal washes with 9 mg nebulised sodium hyaluronate given for 15 days per month over 3 months in 75 paediatric patients with recurrent upper respiratory tract infections (URTI). Eligible patients were randomized to treatment with nasal washes containing 9 mg sodium hyaluronate plus saline solution or saline alone, according to an open-label, parallel group design, with blind observer assessment. Ciliary motility, which was assessed based on a 0-3 point rating scale (0 = absent, 1 = < 5 minutes, 2 =~5 and::: 10 minutes, 3 = > 10 minutes) was the primary study endpoint. The secondary efficacy variables included cytological (presence of neutrophils, eosinophils and mast cells), microbiological (presence of bacteria and mycetes), endoscoplcal (presence of adenoid hypertrophy and biofilm) and clinical (presence of rhinitis, post-nasal drip, nasal dyspnoea) parameters. The two treatment groups (mean age 7.5 years, 53% of males) were comparable for baseline data, except a higher mean age in the control group than in the treated group. Treatment with 9 mg sodium hyaluronate was associated with significantly greater improvements (p<0.001 between groups) in primary outcome ciliary motility [odds ratio (OR) 13.61; 95% CI 4.51-41.00 in the univariate regression analysis that examined the probability of improvement]. Treatment with 9 mg sodium hyaluronate was also significantly superior to saline alone in adenoid hypertrophy (p<0.001; OR 14.72; 95% CI 4.74-45.68), presence of bacteria (p = 0.026; OR 2.95; 95% CI 1.15-7.55), neutrophils (p = 0.002; OR 4.51; 95% CI 1.75-11.62), rhinitis (p = 0.040; OR 10.47; 95% CI 3.10-35.31), nasal dyspnoea (p = 0.047; OR 3.80; 95% CI 1. 09-13.19) and biofilm (p = 0.049; OR 9.90; 95% CI 2.61-37.47). Advantages of9 mg of sodium hyaluronate over control on postnasal drip and presence of mycetes (although evident) did not reach the level of statistical significance. The superiority of the treated group over saline alone was confirmed in a multivariate logistic regression analysis that took into account age as confounding factor. The number of days of absence from school was significantly lower in the 9 mg sodium hyaluronate group compared to controls (p<0.001 between groups). A 3-month intermittent treatment with 9 mg sodium hyaluronate with nasal washes plus saline solution was associated with significant improvements in ciliary motility and in cytological, microbiological, endoscopic and clinical outcomes compared to saline, in children with recurrent URTI.
component of many extracellular matrices, including respiratory epithelial cells and gland serous cells (1) and the nasal and tracheobronchial mucosa (2) .
HA may be an important regulator of the inflammatory process. During inflammation, high molecular weight HA is broken down under the influence of free radicals and enzymes. Lowmolecular-weight fragments deliver signal about tissue damage and mobilize immune cells, while the high molecular weight form suppresses immune cell function preventing excessive exacerbation of inflammation (3) .
HA is present in high concentrations at the laryngeal muscle level and in the subepithelium at the glottic level where it may facilitate mucosal movements. It has been hypothesized that the abundant HA in the subglottic region may be involved in the control of vascular leakage and edema formation (4) . At the nasal mucosa level, HA is involved in the modulation of the activity of substances, such as endothelin-l (ET-l), that play a role on regulation of vasomotor tone and on both serous and mucous gland secretion (5, 6) . Furthermore, it has been recently reported that HA depolymerization during inflammatory responses may be directly involved in the induction of mucus hypersecretion (7) .
From a clinical perspective, the effects of the use of HA in different therapeutic applications, particularly in the treatment of arthritis, have been largely demonstrated (8, 9) . Although HA seems to playa key role in modulating airway inflammation by inhibiting migration, chemiotaxis and aggregation of polymorphonuclear leucocytes and monocytes (10, 11) , there is little documentation on its clinical effects in the treatment of inflammatory respiratory diseases. Evidence from literature indicates that the use of aerosolised HA may reduce induced bronchial hyper-reactivity in asthmatic patients (11) , as a result of a possible counteracting activity on the pathological remodelling of bronchial wall composition. When administered subcutaneously, HA was beneficial in reducing the number of infectious exacerbations in patients with recurrent acute exacerbations of chronic bronchitis, possibly by enhancing cellular host defence mechanisms (12) . With regard to intranasally administered HA, it was recently reported that injections of an HA gel preparation into the inferior nasal concha and under the mucous membrane of the septum was associated with improvements of symptoms of rhinitis which persisted over time (13) .
This pilot study was carried out to investigate whether the use a of nasal wash device in which 9 mg sodium hyaluronate is added to saline solution would improve ciliary motility compared to the use of saline solution alone in upper respiratory tract infections (URTI) in children attending our clinic. Furthermore, the effects of washes on cytological, bacteriological and endoscopic variables were evaluated in this study.
MATERIALS AND METHODS

Patients
Participants gave their written informed consent prior to entering the study. The study protocol and the informed consent form were reviewed and approved by the reference Ethics Committees ofthe study site before any studyrelated procedure was started. The study was randomized, double-blind, parallel group, and placebo-controlled.
The study group included 75 pediatric patients with recurrent upper respiratory tract infections (URTI). The infection types included in the study were rhinitis, rhinosinusitis, adenoiditis, pharyngitis, otitis media, tubotympanitis and tonsillitis. The patients with these recurrent pathologies were: 17 affected by rhinitis, 8 by rhinosinusitis, 27 by adenoiditis, 3 by pharyngitis, 13 by otitis media, 5 by tubotympanitis and 2 by recurrent tonisillitis.
Patients with history ofimmunological or autoimmune diseases, genetic syndromes, malformations or presenting with any indication for surgery were excluded from study participation.
Treatments
Selected patients started aerosol-therapy with nasal washes by using a device allowing nebulisation ofparticles with a median aerodynamic diameter> 5 micron over a nebulisation time of 60-90 seconds for any application. Intermittent treatment was administered twice daily for 15 consecutive days per month, for three consecutive months. The patients were double-blind randomized to receive one 9 mg vial of sodium hyaluronate plus 3 ml saline (SH group), or 6 ml saline alone (control group). The compliance to the assigned treatment was evaluated by counting the amount of dispensed and returned vials.
Outcome measures
Ciliary motility was the primary study endpoint and was assessed by the contrast-phase microscopy analysis. Evaluation was based on a 0-3 point rating scale, where; o= absent, 1 = < 5 minutes, 2 = 2' : 5 and:oS 10 minutes, 3 = > 10 minutes. The ciliary motility was assessed at the first clinical evaluation and at all control visits carried out after therapy administration (Visit 1 and Visit 2).
A semiquantitative scale was also used for the assessment of the secondary efficacy variables, as follows: adenoid hypertrophy, estimated by direct endonasal endoscopic view (1 = grade 1, 2 = grade 2, 3 = grade 3, 4 = grade 4), presence ofneutrophils, eosinophils and mast cells, assessed by direct evaluation at optical microscopy based on the number of cell/microscopic field (0 = absent, 1 = few cells, 3 = medium amount, 4 = many cells, 5 = very many cells) and presence of bacteria (0 = absent, 1 = few bacteria, 3 = 4 = many bacteria, 5 = very many bacteria). The following other efficacy parameters were evaluated according to a dichotomic scale: presence of rhinitis (0 = none, 1 = > 5 episodes), and post-nasal drip, basal dyspnoea, mycetes and biofilm (0 = absent, 1 = present).
Thus, a higher score for ciliary motility corresponds to a better outcome, whereas a higher score for the other variables is indicative of a worse outcome. Assessments of cytological, microbiological, endoscopic and clinical outcomes were performed in blind condition by an investigator who was unaware of the assigned treatment. Finally, the children recorded the number of days of absence from school during the 3 months of treatment.
Statistics
Continuous variables were presented as median and interquartile range (IQR) or mean and standard deviation (SD), when appropriate, while absolute and relative frequencies were reported for proportions. To test differences at baseline between the two groups oftreatment, the Wilcoxon-Mann-Whitney test was used for continuous and quantitative variables and the Fisher's exact test was used for proportions. In the comparisons between groups, the Wilcoxon test was used for quantitative variables and the Fisher's exact test was used for dichotomic variables. Univariate and multivariate logistic ordinal models were used to measure the effect of treatment and control unadjusted and adjusted for potential confounders (age), respectively: the results of these analyses were presented as crude and adjusted odds ratio (OR), and 95% confidence interval (CI), with DRs indicating the relative increase of the probability of improvement in the outcome associated to the active treatment. All tests were two-tailed at the 0.05 significance level. Table I shows the baseline characteristics of pa-tients in the two groups. The two treatment groups (38 patients in the treated group and 37 in the saline group) were comparable for demographic data and the other baseline data, except a significantly higher mean age in the control than in the SH group (p = 0.029 between groups).
RESULTS
Baseline characteristics
Efficacy
The results of quantitative variables (Table II) showed statistically significant differences, in favour ofthe SH group, for the primary endpoint ciliary motility (p<0.001), as well as for adenoid hypertrophy (p<0.001) and presence of bacteria (p = 0.026) and neutrophils (p = 0.002). No statistically significant differences between groups were reported for presence of eosinophils and mast cells, due to no change in category from baseline to end of treatment for eosinophils and only one case of improvement for mast cells in each group. Table III shows the results of dichotomic variables in the two groups. Treatment with 9 mg of sodium hyaluronate was associated with statistically significant improvements compared to saline alone for rhinitis (p = 0.040), nasal dyspnoea (p = 0.047) and biofilm (p = 0.049), while the difference between groups for post-nasal drip and mycetes was not significant (although favouring HA).
Figs. I and II shows the odds ratio for the examined primary and secondary endpoints, unadjusted (univariate) and adjusted for age (multivariate), respectively. The results are indicative of a higher probability of improvement (i.e. an OR > 1) with 9 mg sodium hyaluronate treatment compared to controls for all examined variables (except for mast cells). With regard to the primary endpoint ciliary motility and to adenoid hypertrophy, treatment with 9 mg sodium hyaluronate was associated with a probability of success more than 10 times greater than that observed in the control group. OR was not calculated for eosinophils, as there were no changes from baseline to endpoint for this variable in both groups.
As shown in Fig. II , the use of the multivariate logistic model (adjusted for age) substantially confirmed the findings observed in the univariate analysis. A statistically significant unadjusted OR corresponded to a significant adjusted OR for most of examined variables, except for mycetes, which was The analysis of the number of days of absence from school showed a statistically significant difference (p<0.001) in favour ofthe SH group (median 1, IQR 0-4) compared to the control group (median 4, IQR 3-10).
DISCUSSION
M ucociliary clearance is a key defence mechanism in human upper and lower airways and its impairment predisposes to chronic infections of the nose, paranasal sinuses and respiratory tree (14) . Nasal mucociliary clearance is the first-line physiological function of nasal cavity that helps in protecting the lower respiratory tract from undesirable organic and inorganic matter, including microorganisms (15) . Multiple investigations have demonstrated a marked decrease in nasal mucociliary clearance in patients with rhinitis or chronic rhinosinusitis (16) (17) (18) . On the other hand, acute URTIs may reduce the nasal mucociliary defence by directly damaging the cilia and by changing the rheological properties of the nasal secretions (19, 20) , thus leading to maintenance or worsening of the inflammatory state. Recent findings suggest that low molecular weight HA protects the airway epithelium against injury induced by bacterial products during infection by acting as a lubricant at the airway epithelium surface, thus suggesting that HA may play a therapeutic role in a variety of respiratory diseases (21) . Its high concentration in the upper and lower airways positively influences bio-mechanical forces, hydric balance, cellular functions, activity of growth factors and cytokine behaviour (11) .
Based on the known background of the effects of HA in the regulation of vasomotor tone and mucous gland secretion, and in the modulation of the inflammatory process, this pilot study was carried out to assess whether intermittent cycles of nebulised of HA given as nasal washes in addition to saline solution would improve ciliary motility, nasal mucosa cellularity and inflammatory status in children with recurrent URTIs, compared to nasal washes with saline solution alone. To our knowledge, this is the first study that has evaluated the effects of aerosolised HA on a spectrum of cytological, microbiological, endoscopical and clinical outcome measures, including the evaluation of the adenoid volume and of the endonasal secretions.
Although no formal sample size calculation was performed due to the explorative nature of the study, ciliary motility was considered as the primary study endpoint in view of the recognised role of ciliary beating as first-line defence mechanism and on the known effects ofHA in modulating ciliary activity. In this respect, Forteza and colleagues (22) demonstrated that HA plays a pivotal role in mucosal host defence by stimulating ciliary clearance of foreign material while simultaneously retaining enzymes important for homeostasis at the apical surface. Moreover, tissue kallikrein and lactoperoxidase, which are involved in the prevention of airway bacterial colonization and in the mediation of allergic bronchoconstriction that limits the inhalation of noxious substances, respectively, are bound to the airway epithelial surface by HA and are not cleared by ciliary beating.
The median ciliary motility score was equal to 1 (i.e. corresponding to < 5 minutes) in both treatment groups. Importantly, although the mean age (6±3 years in the SH group and 7±2 years in the control group) was significantly different between groups, patients in this study were in an age range in which nasal mucociliary clearance may be impaired probably due to subclinical adenoiditis (15) . Therefore, both the age-related and the URTI-related impairment of ciliary motility led to the selection of patients with adequate room for improvement and hence to the possibility of detecting differences between groups, if any. At the end of observation, the median ciliary motility remained unchanged in the groups ofpatients that performed saline nasal washes, while it improved to a median score of2 (i.e. corresponding to the range 2: 5 and s 10 minutes) in the SH group of patients, with a significant proportion of patients with score 3 (> 10 minutes) at endpoint, as shown by the upper IQR value in this group. The difference between groups was statistically significant (p<O.OO 1).
Statistically significant benefits in the SH group of patients over controls were also observed in cytological (presence ofneutrophils), microbiological (presence of bacteria), endoscopical (presence of adenoid hypertrophy and bio film) and clinical (presence ofrhinitis and nasal dyspnoea) parameters. Although favouring the SH group of patients, the improvements from baseline in post-nasal drip and presence of mycetes were not different between groups. The presence of eosinophils and mast cells did not change from baseline in either group. The results ofthe multivariate logistic regression analysis that took into account the difference in mean age between groups, which might account for a different ciliary motility at baseline in the two groups, did not substantially differ from those observed in the primary analysis. The lack ofa statistically significant difference between groups for some variables (e.g. post-nasal drip) may be explained taking into account that nasal washes with saline solution may be beneficial, as documented in literature (23-25) on post-nasal drip and nasal patency, thus rendering the study not adequately powered in terms of sample size for detecting further significant benefits with the addition of 9 mg sodium hyaluronate to saline solution.
From a health-economic perspective, this study showed that improvements in clinical condition were associated with a significant reduction of the number of days of absence from school in the SH group compared to controls.
Despite the promising results, this study has some limitations. Firstly, in the interpretation of the results it should be considered that this was a pilot study that included a relatively small number ofpatients in both groups, therefore the study may be not adequately powered to demonstrate the superiority of treatment with 9 mg of sodium hyaluronate over saline alone in all examined variables. Second, the study included a heterogeneous population of children with recurrent URTIs and the limited number of patients did not allow subgroup analysis for each specific disease. Thus, it would be of interest to assess in further trials whether the use of9 mg ofsodium hyaluronate added to saline nasal washes would be more beneficial in any specific type URTI over the others. Finally, patients in this study were exposed to a relatively short period of treatment (three intermittent cycles of 15 days), therefore, it would be of interest to investigate both the therapeutic and preventive effects of 9 mg of sodium hyaluronate over a longer exposure to treatment, particularly i~non-seasonal diseases.
In conclusion, this study provides clear evidence in support of the effectiveness of treatment with 9 mg of sodium hyaluronate as aerosolised nasal washes in children with recurrent URTIs. Further research on larger samples of patients is needed to confirm the potential place in therapy of9 mg sodium hyaluronate in inflammatory respiratory diseases.
